Sugi Predict

Sugi Predict / Compounds / SCHEMBL16010071

SCHEMBL16010071

SCHEMBL16010071

CC(C)C[C@H](CO)Nc1ccc2ncc(-c3cc4ccccc4s3)n2n1

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.57
▸ PIK3R1 P27986 1/20 0.57
▸ DYRK1A Q13627 14/20 0.55
▸ DYRK2 Q92630 14/20 0.55
▸ DYRK1B Q9Y463 14/20 0.55
▸ DYRK3 O43781 13/20 0.55
▸ CCNT1 O60563 13/20 0.55
▸ CDK9 P50750 13/20 0.55
▸ CDK5 Q00535 12/20 0.55
▸ CDK5R1 Q15078 12/20 0.55
▸ CCNA2 P20248 11/20 0.55
▸ CDK2 P24941 11/20 0.55
▸ FYN P06241 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16009801 1.00 PIK3CD (0.57) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16009799 1.00 PIK3CD (0.57) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16009518 0.89 DYRK1A (0.47) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16009517 0.89 DYRK1A (0.47) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16009537 0.89 DYRK1A (0.47) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16016976 0.86 FYN (0.62) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16016975 0.86 FYN (0.62) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16023623 0.86 FYN (0.62) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16010458 0.83 PIK3CD (0.64) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B
SCHEMBL16010044 0.82 PIK3CD (0.56) PIK3CDPIK3R1DYRK1ADYRK2DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. 2016-08-11 — — US disclosed
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. 2016-08-11 — — US disclosed
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. 2016-08-11 — — US disclosed
US-9370515-B2 Mixed lineage kinase inhibitors and method of treatments Califia Bio, Inc. (US) 2016-06-21 — — US disclosed
US-9370515-B2 Mixed lineage kinase inhibitors and method of treatments Califia Bio, Inc. (US) 2016-06-21 — — US disclosed
US-9370515-B2 Mixed lineage kinase inhibitors and method of treatments Califia Bio, Inc. (US) 2016-06-21 — — US disclosed
WO-2014138692-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. (US) 2014-09-12 — — WO disclosed
US-20140256733-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. (US) 2014-09-11 — — US disclosed
US-20140256733-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. (US) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS MAP3K2, MAP3K1, MAP3K20 PIK3CD 316/4885PIK3R1 436/4885DYRK1A 442/4885
US-20140256733-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS MAP3K2, MAP3K1, MAP3K20 PIK3CD 316/4885PIK3R1 436/4885DYRK1A 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.